As the study included otherwise healthy patients with known malignancies, the results need to be confirmed with prospective studies of incidence cancer types in a large population. Patients in the screening setting may have less advanced disease and other comorbidities that could impact the sensitivity and specificity of the CancerSEEK test, the researchers wrote.
The study was funded by multiple sources including grants from the National Institutes of Health. The authors reported various disclosures involving diagnostics and pharmaceutical companies.
SOURCE: Cohen JD et al., Science 2018 Jan 18. doi: .